| Autor: |
Fleishaker, Joseph C., Herman, Beth D., Carel, Barbara J., Azie, Nkechi E. |
| Zdroj: |
Journal of Clinical Pharmacology; April 2003, Vol. 43 Issue: 4 p423-427, 5p |
| Abstrakt: |
The interaction between almotriptan, a 5‐HT1B/1Dagonist, and the potent CYP3A4 inhibitor ketoconazole was examined in 16 healthy volunteers. Subjects received (A) 12.5 mg almotriptan orally on Day 2 of a 3‐day regimen of 400 mg ketoconazole once daily and (B) 12.5 mg almotriptan in a crossover design. Plasma and urine concentrations of almotriptan were measured by HPLC. Treatment effects on almotriptan pharmacokinetics were assessed by analysis of variance. Ketoconazole coadministration increased mean almotriptan AUC and Cmaxfrom 312 to 490 ng h/mL and 52.6 to 84.5 ng/mL, respectively. Mean oral clearance was decreased from 40.7 to 26.2 L/h by ketoconazole, with an accompanying increase in the fraction of almotriptan excreted unchanged in the urine (40.6% to 53.3%) and a decrease in renal clearance (16.4 to 13.8 L/h). These effects were statistically significant. The effects of ketoconazole on almotriptan clearance were consistent with inhibition of the CYP3A4‐mediated metabolism and a slight effect on the active tubular secretion of almotriptan. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
Plný text